Overall, the contradictory observations of PIAS3 effects in TNBC and HR-positive breast cancer may suggest that different effects of PIAS3 on breast cancer cells may involve ER, whereas therapeutic targeting of SUMOylation and PIAS1 may be an effective strategy for the treatment of MYC-dependent breast cancers. This evidence concerns the gene PIAS1 and breast carcinoma.